Marker Therapeutics Reports MT-401 Non-Clinical Data in AML
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of the Development of MT-401 for the Treatment of AML Patients ...
Source: globenewswire.com
Front Oncol News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Front Oncol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Front Oncol Today - Breaking & Trending Today
Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...
Source: prnewswire.com
Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors
/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...
Source: prnewswire.com
Frontiers | Extracellular Vesicle Mediated Tumor-Stromal Crosstalk Within an Engineered Lung Cancer Model
1* 1Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, United States 2Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, United States 3Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, United States 4Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL, United States Tumor-stromal interactions within the tumor microenvironment (TME) influence lung cancer progression and...
Source: frontiersin.org